Charlotte Rosso1, David Rosenbaum2, Christine Pires3, Corinne Cherfils4, Nabil Koujah4, Fouzi Mestari4, Emeline Gillet4, Sophie Crozier3, Mélika Sahli-Amor5, Yves Samson6, Dominique Bonnefont-Rousselot7, Randa Khani-Bittar8. 1. CRICM-Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR, Paris, France; COGIMAGE, UPMC Paris 6, Paris, France; APHP, Urgences Cérébro-Vasculaires, Hôpital Pitié-Salpêtrière, Paris, France. Electronic address: charlotte.rosso@psl.aphp.fr. 2. Unité de prévention des maladies cardiovasculaires, Hôpital Pitié-Salpêtrière, Paris, France; Laboratoire d'imagerie fonctionnelle, INSERM U678, UPMC Paris 6, Paris, France. 3. APHP, Urgences Cérébro-Vasculaires, Hôpital Pitié-Salpêtrière, Paris, France. 4. APHP, Service de Biochimie Métabolique, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Paris, France. 5. APHP, Service de Neuroradiologie, Hôpital Pitié-Salpêtrière, Paris, France. 6. CRICM-Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, UPMC Paris 6, Inserm, U975, CNRS, UMR, Paris, France; COGIMAGE, UPMC Paris 6, Paris, France; APHP, Urgences Cérébro-Vasculaires, Hôpital Pitié-Salpêtrière, Paris, France. 7. APHP, Service de Biochimie Métabolique, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Paris, France; EA 4466, Département de Biologie Expérimentale, Métabolique et Clinique, Faculté de Pharmacie, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 8. APHP, Service de Biochimie Métabolique, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Paris, France; UPMC Université Paris 06, Paris, France.
Abstract
BACKGROUND: The objectives of the study were to compare lipoprotein-associated phospholipase A2 (Lp-PLA2) levels in a prospective cohort including both ischemic and hemorrhagic strokes at the hyperacute phase, and to investigate if these levels were associated with stroke severity. MATERIALS AND METHODS: Lp-PLA2 mass and activity were measured during the first 6 hours of symptom onset before any therapeutic intervention. The Lp-PLA2 level was analyzed by comparing the mass and activities in ischemic strokes and spontaneous intracerebral hemorrhages (ICH). Correlations between Lp-PLA2 levels and clinical scores as well as stroke volumes were made. The temporal evolution of Lp-PLA2 during the first week was analyzed in ischemic stroke patients. RESULTS: Lp-PLA2 mass was higher in ICH than in ischemic stroke (P = .001). Lp-PLA2 activity at admission correlated with initial and follow-up stroke volume in ICH (P = .003 and P = .004, respectively) but not in ischemic stroke. None of the measurements correlated with clinical severity for either diagnosis. Lp-PLA2 mass decreased during the first week after the use of statins in ischemic stroke, whereas the activity remained stable. CONCLUSIONS: Lp-PLA2 mass is higher in ICH compared with ischemic stroke during the hyperacute stage. Lp-PLA2 activity is associated with stroke volume in ICH but not in ischemic stroke. This suggests that Lp-PLA2 mass and activity could provide different information in the hyperacute stage of stroke.
BACKGROUND: The objectives of the study were to compare lipoprotein-associated phospholipase A2 (Lp-PLA2) levels in a prospective cohort including both ischemic and hemorrhagic strokes at the hyperacute phase, and to investigate if these levels were associated with stroke severity. MATERIALS AND METHODS:Lp-PLA2 mass and activity were measured during the first 6 hours of symptom onset before any therapeutic intervention. The Lp-PLA2 level was analyzed by comparing the mass and activities in ischemic strokes and spontaneous intracerebral hemorrhages (ICH). Correlations between Lp-PLA2 levels and clinical scores as well as stroke volumes were made. The temporal evolution of Lp-PLA2 during the first week was analyzed in ischemic strokepatients. RESULTS:Lp-PLA2 mass was higher in ICH than in ischemic stroke (P = .001). Lp-PLA2 activity at admission correlated with initial and follow-up stroke volume in ICH (P = .003 and P = .004, respectively) but not in ischemic stroke. None of the measurements correlated with clinical severity for either diagnosis. Lp-PLA2 mass decreased during the first week after the use of statins in ischemic stroke, whereas the activity remained stable. CONCLUSIONS:Lp-PLA2 mass is higher in ICH compared with ischemic stroke during the hyperacute stage. Lp-PLA2 activity is associated with stroke volume in ICH but not in ischemic stroke. This suggests that Lp-PLA2 mass and activity could provide different information in the hyperacute stage of stroke.